Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)
Date
2023-06-10ICR Author
Author
Loriot, Y
Matsubara, N
Park, SH
Huddart, RA
Burgess, EF
Houede, N
Banek, S
Laguerre, B
Guadalupi, V
Ku, JH
Triantos, S
Akapame, S
Deprince, K
Mukhopadhyay, S
Siefker-Radtke, AO
Type
Conference Proceeding
Metadata
Show full item recordCollections
Research team
Clinic Acad RT Huddart
Language
eng
Date accepted
2023-09-11
License start date
2023-06-10
Citation
Journal of Clinical Oncology, 2023, 41 (17),
Publisher
LIPPINCOTT WILLIAMS & WILKINS